+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06130553

Study of AZD3470 as Monotherapy and Combined with Datopotamab Deruxtecan in Adults with MTAP Deficient Advanced or Metastatic Solid Tumors

Led by AstraZeneca · Updated on 2026-08-27

334

Participants Needed

21

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AZD3470, a new type of drug called a PRMT5 inhibitor, in adults with advanced or metastatic solid tumors that have a specific deficiency called MTAP. This Phase IIIa open-label study aims to understand the safety, tolerability, how the drug moves in the body, and early signs of effectiveness. The study is multi-centre and involves several parts to explore AZD3470 alone or combined with other anti-cancer treatments. The study includes different modules Module 1 focuses on finding the right dose by testing increasing amounts of AZD3470 and then optimizing the dose and expanding participant numbers. Module 2 evaluates AZD3470 combined with another drug, Datopotamab deruxtecan Dato-DXd, compared to Dato-DXd alone, looking closely at safety and effectiveness. Participants receive varying doses depending on their group, and new combination treatment modules may be added later based on study results. Participants will provide tumor tissue samples for testing and will be monitored regularly for side effects, treatment response, and drug levels in the body. Assessments include scans following RECIST v1.1 criteria to measure tumor changes, along with safety checks and laboratory tests. The study measures outcomes such as adverse events, progression-free survival, and overall survival, with follow-up lasting up to about two years after treatment. The total participation duration varies based on treatment and response.

CONDITIONS

Brief Title

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here